As gene therapies advance toward indications with larger patient populations, adeno-associated virus (AAV) manufacturers are under growing pressure to deliver high-quality vectors at substantially ...
Delivers 2x increase in AAV titers compared to market alternates. Reduce plasmid input, halve the bioreactors, and significantly lower cost per dose. HORSHAM, Pa., Aug. 12, 2025 /PRNewswire/ -- In a ...
- AAV-SLB101 is the capsid used in SGT-003, Solid’s next-generation Duchenne gene therapy, expected to enter the clinic in late-2023 - - Additional novel capsids based on AAV-SLB101 binding protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results